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Abstract 
Background. Primary ovarian carcinoma with metastasis to the breast is rare, with only 39 
cases reported in the current literature. Ovarian metastasis to the breast presenting as in-
flammatory breast carcinoma is even more infrequent, with only 6 cases reported.  
Case. We present a patient who developed metastatic inflammatory cancer of the breast from 
a stage IIIC papillary serous ovarian adenocarcinoma approximately 1 year after the original 
diagnosis. Pathologic analysis confirmed the origin of the tumor: a high-grade adenocarcinoma 
morphologically similar to the previously diagnosed ovarian cancer. In addition, the tumor was 
strongly positive on immunohistochemistry for CA-125, identical to the ovarian primary. The 
patient died of diffuse metastasis 5 months after the breast tumor was noted. 
Conclusion. Although ovarian metastasis to the breast presenting as inflammatory breast 
cancer is rare, it should be included in the differential diagnosis for any patient with a personal 
history of ovarian cancer. Accurate differentiation is necessary because treatment differs 
significantly for patients with ovarian metastasis to the breast, as compared with patients with 
primary inflammatory breast cancer. Ovarian metastasis to the breast confers a poor 
prognosis: patient survival ranged from 3 to 18 months, with a median survival of 6 months 
after the diagnosis of the breast metastasis.  
Key words: breast cancer, ovarian cancer, inflammatory breast cancer, ovarian cancer metastasis, 
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Case Report 
Our patient, a 60-year-old woman, originally 
presented to her primary care physician for pelvic 
discomfort in September 2006. At that time, she un-
derwent a pelvic ultrasound as well as a computed 
tomography (CT) scan of the abdomen and pelvis, 
which showed a complex ovarian mass. A Pap smear 
performed one month later was positive for atypical 
glandular cells suspicious for adenocarcinoma. In 
November 2006, she underwent a total abdominal 
hysterectomy with bilateral salpingoophorectomy, 
omentectomy, and periaortic lymphadenectomy. 
Upon intraoperative exam, her surgeons noted in-
volvement of the omentum and appendix, as well as 
studding of the small bowel mesentery and right di-Journal of Cancer 2010, 1 
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aphragm. The pathologic specimen showed extension 
of the tumor throughout the fallopian tubes, appen-
dix, omentum, and 5 out of 5 positive lymph nodes. 
The final pathologic diagnosis of the tumor was stage 
IIIC papillary serous ovarian adenocarcinoma. The 
patient underwent placement of an intraperitoneal 
catheter and an intravenous Port-A-Cath for initiation 
of chemotherapy in December 2006. 
The remainder of the patient’s past medical his-
tory is noncontributory as she was previously in ex-
cellent health prior to the diagnosis of ovarian cancer. 
In addition, she had no known family history of ova-
rian or breast cancer. 
Her initial chemotherapeutic regimen was 
intraperitoneal and intravenous cisplatin and Taxol. 
Unfortunately, she suffered a hypersensitivity reac-
tion to the Taxol, and was therefore switched to car-
boplatin and Abraxane. She received a total of 8 cycles 
of that combination, with only 1 cycle postponed 
secondary to neutropenia. Just before the 8th cycle, in 
order to assess her response to treatment, she under-
went a CT scan of the chest, abdomen, and pelvis. The 
CT scan showed persistent disease around the vaginal 
cuff. In addition, her CA-125 level, which had pre-
viously reached a plateau of 30 U/ml, had risen to 123 
U/ml.  
Concerned about the possibility of drug-resistant 
disease, she was evaluated for enrollment in a trial of 
Avastin and Tarceva. She underwent a new CT scan 
of the chest, abdomen, and pelvis, in order to obtain 
baseline data for the trial (3 months after her previous 
CT scan). The new CT scan showed interval devel-
opment of right axillary lymphadenopathy; the larg-
est lymph node was 1.1 x 1.8 cm and suspicion of a 
new primary breast cancer was raised. We proceeded 
with breast magnetic resonance imaging (MRI) with 
gadolinium which showed no suspicious lesions or 
masses. She therefore continued on Avastin and Tar-
ceva. However, she developed a significant rash in 
association with these drugs and required dose re-
duction.  
In October 2007, almost a year after her initial 
ovarian cancer diagnosis, the patient reported the 
new-onset of right breast edema. Although she had 
been previously followed for the right axillary lym-
phadenopathy, she had recently noticed an increase in 
erythema, thickness, and warmth of the skin of her 
right breast [Fig 1, 2]. She was treated with a 10-day 
c o u r s e  o f  a n t i b i o t i c s ,  w i t h  n o  c h a n g e  i n  s y m p t o m s .  
She then underwent an ultrasound of her breast that 
showed an ill-defined hypoechoic area in the right 
upper outer quadrant with multiple enlarged lymph 
nodes. A subsequent mammogram showed scattered 
fibroglandular densities and an area of architectural 
distortion with a few small punctate calcifications. 
Her gynecologic oncologist performed a fine-needle 
aspiration of the breast, which showed cells consistent 
with adenocarcinoma. She then underwent a second 
bilateral breast MRI, which confirmed the presence of 
an area of heterogeneous enhancement measuring 8 x 
4 cm, highly suggestive of cancer, with areas suspi-
cious for tumoral extension to the chest wall [Fig 3, 4]. 
Because of these findings, the patient was re-
ferred to a breast surgical oncologist, who performed 
a punch biopsy of her right breast. Pathologic analysis 
showed multiple foci of high-grade adenocarcinoma 
with dermal lymphatic invasion, with morphology 
similar to that of the previous ovarian cancer [Fig 5]. 
Furthermore, the breast tissue specimen immunohis-
tochemistry results were positive for CA-125, but 
negative for estrogen receptor (ER), progestin recep-
tor (PR), and the HER-2/neu oncoprotein. Upon re-
view by our institution’s multidisciplinary tumor 
board, it was concluded that these results were con-
sistent with an ovarian primary tumor. 
 
 
Figure 1. Picture demonstrating the inflammatory changes 
present on initial presentation. 
 
Figure 2. Picture demonstrating the size discrepancy be-
tween the two breasts.  Journal of Cancer 2010, 1 
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Figure 3. MR images (T1, T2, post-contrast subtracted and 
MIP) demonstrating a large segmental area of heteroge-
neous enhancement in the right central breast. There is also 
abnormal skin enhancement, thickening and edema (straight 
arrows) consistent with inflammatory changes related to 
dermal lymphatic involvement. Significant right axillary 
lymphadenopathy is also present (curved arrow).  
 
 
Figure 4. Post contrast subtracted with CAD stream MR 
image shows a 7.8 cm x 4.2 cm heterogeneously enhancing 
mass containing several foci of rapid washout (Type III 
kinetics) compatible with carcinoma. 
 
Discussion 
Breast cancer is one of the most common pri-
mary malignancies in women, yet metastatic tumors 
to the breast are infrequent, accounting for only 0.5% 
to 1.3% of breast cancer cases [1]. The most common 
source of metastasis to the breast is a contralateral 
primary breast tumor, frequently from transthoracic 
or lymphatic spread. However, hematogenous me-
tastasis from extramammary malignancies has been 
reported [2]. A study by Hadju and Urban involving 
4,051 breast cancer patients found an overall inci-
dence of primary gynecologic cancers metastatic to 
the breast of 0.17%, with only 0.07% of metastatic 
disease originating from a primary ovarian tumor [3]. 
The first case report of ovarian cancer with metastasis 
to the breast was in 1907 by Sitzenfrey [4]. To date, a 
total of only 39 such cases have been reported in the 
English-language literature [5].  
Ovarian metastasis to the breast mimicking 
primary inflammatory breast carcinoma is even more 
infrequent, with only 6 previous cases reported [Table 
1]. Inflammatory metastasis to a single breast was first 
reported by Ibach in 1964 [6], followed by 5 other case 
reports [2, 4, 7, 8, 9]. Of note, the most recent patients, 
including ours, all had a diagnosis of stage IIIC pa-
pillary serous adenocarcinoma.  
In contrast to primary breast tumors, metastasis 
to the breast generally consists of firm, 
well-circumscribed, multinodular masses. In addition, 
the masses are usually superficial and less fixed to 
surrounding tissues, with the overlying skin generally 
of normal consistency. The most common form of 
clinical presentation (in 85% of patients) was a solitary 
tumor; only 4% of patients had diffuse involvement 
[4]. Furthermore, the most common location was the 
upper outer quadrant in 62% of patients [3]. 
Radiographically, mammographic evaluation 
can provide additional information. Metastatic tu-
mors to the breast more frequently present as 
well-circumscribed, non-calcified dense masses. They 
generally lack spiculation and microcalcifications as 
well as architectural distortion and other skin 
changes. However, because of the presence of psam-
moma bodies associated with some ovarian cancers, 
microcalcifications can be seen with ovarian metasta-
sis [3, 10]. 
 
 
Figure 5. Intermediate power microscopic image depicting 
metastatic tumor cells involving superficial dermal lym-
phatics. 
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Breast metastasis from a primary ovarian tumor, 
however, commonly lacks a characteristic pattern, 
may be morphologically indistinguishable from its 
primary, and is associated with widespread dissemi-
nation. In addition, breast metastasis from a primary 
ovarian tumor generally is diagnosed an average of 2 
years after the initial diagnosis of ovarian cancer [2]. 
Our patient developed a markedly diffuse inflamma-
tory process of her right breast with features consis-
tent with inflammatory breast cancer within 1 year 
after her initial diagnosis.  
Histopathological analysis of breast and ovarian 
tumors can yield similar results. Therefore, accurate 
differentiation is necessary, because treatment and 
prognosis differ significantly. The most common his-
tologic variant of ovarian cancer associated with me-
tastatic disease to the breast is papillary serous ade-
nocarcinoma [3]. Immunohistochemistry may provide 
additional insight into the origin of the tumor. By 
combining the tumor markers OC125 and OV632, 
Yamaski et al. found a sensitivity of 86% and a speci-
ficity of 89% for the diagnosis of metastatic ovarian 
cancer [10].  
Secondary breast involvement from an ovarian 
tumor suggests widespread dissemination and is as-
sociated with a poor prognosis. According to several 
studies, after the detection of metastatic breast disease 
secondary to an ovarian primary tumor, survival 
times ranged from 13 days to 3.5 years [2], with most 
patients dying within 1 year [11]. Another study 
found a 1-year survival rate of 40% for patients with 
ovarian cancer who also had breast metastasis, as 
opposed to a 4-year survival rate of 75% for patients 
with primary breast cancer [12]. Inflammatory me-
tastatic disease to the breast also confers a grave 
prognosis: patient survival ranges from 3 to 18 
months (median, 6 months) after diagnosis of the 
metastasis to the breast [Table 1]. Our patient died of 
diffuse metastasis 5 months after the breast tumor was 
noted. 
Extramammary tumors should be distinguished 
from primary breast tumors to avoid any unnecessary 
surgical procedures. Correct diagnosis is vital: sur-
gical interventions for patients with secondary breast 
cancers are potentially both diagnostic and palliative. 
Ovarian metastasis to the breast should be treated as a 
systemic disease, with appropriate chemotherapeutic 
agents. Mastectomy of the breast mass is likely best 
reserved for patients who are unresponsive to sys-
temic therapy and require palliation [11].  
 
Table 1. Reported Cases of Ovarian Cancer Metastastic the Breast Presenting as Inflammatory Cancer 
CASE  AUTHOR  DATE  TYPE OF OVARIAN TUMOR  SURVIVALa INTERVAL TIME TO 
DIAGNOSISb 
THERAPY 
1 Ibach  1963  Cyst-adenocarcinoma  8  months  2 months  Chemotherapy (Cyclophospha-
mide) 
2 Krishnan  1980  Papillary  Adenocarcinoma  6 months  10 months  Chemotherapy (Cytoxan, Metho-
trexate, Leucovorin) and 
Radiation 
3 Ozguroglu 1999 Papillary Serous Adenocarcinoma  3 months  2 years  Chemotherapy 
4 Fondrinier  1999  Papillary Serous Adenocarcinoma  3 months  3 years  Chemotherapy 
5 Kayik-
cioglu 
2001  Papillary Serous Adenocarcinoma  18 months  18 months  Chemotherapy (Paclitaxel, Cispla-
tin, Anthracycline) 
6  Sato  2007  Clear Cell Carcinoma  10 months  22 months  Chemotherapy 
Current 
Case 
Klein  2008  Papillary Serous Adenocarcinoma  5 months  12 months  Chemotherapy (Cisplatin, Gemci-
tabine) 
a Time from diagnosis of inflammatory breast lesion to death 
b Time from diagnosis of ovarian cancer to breast lesion 
 
Conclusion 
Although ovarian metastasis to the breast pre-
senting as inflammatory breast cancer is rare, it 
should be included in the differential diagnosis for 
any patient with a personal history of ovarian cancer. 
Accurate differentiation is necessary because treat-
ment differs significantly for patients with ovarian 
metastasis to the breast, as compared with patients 
with primary inflammatory breast cancer. Ovarian 
metastasis to the breast confers a poor prognosis: pa-
tient survival ranged from 3 to 18 months, with a 
median survival of 6 months after the diagnosis of the 
breast metastasis.  
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